Drugs / Conventional BCG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03213405 Comparator | Jun 2017 → Jun 2018 | respiratory syncytial virus infectious disease | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conventional BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03213405 ↗ |
| Modality | Vaccine | “the control vaccine (Conventional BCG)” NCT03213405 ↗ |
| Route | Other | “2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.” NCT03213405 ↗ |